Zip
Denner’s primary objective is to make money for himself and his fund. If he sees better prospects coming up he may feel Amarin is tying up his cash and want to move on. The more companies he can flip the more money he makes.
Amarin got screwed by a corrupt legal system and by a German government that had no plan to actually negotiate (selecting a $30/month comparator doomed the process immediately). They slashed expenses and did a great job negotiating UK reimbursement.
China is a lost cause that will never generate any money. As soon as Amarin lost the patent case, the Chinese government inexplicably delayed approval by at least a year. They obviously had a plan to allow for a Chinese generic to enter the market.
Negotiations with other countries are moving along as scheduled.
What else can Denner do? Secure a $100M loan to ensure no dilution? That is what Amarin needs. He may be able to do that but that doesn’t appear to be his specialty. He carves up companies, trims fat, focuses on profitable aspects of a company. Amarin as a single drug company doesn’t have these options.
News 
Market Data 
Discover 
AI
